Bayer's Rivaroxaban Submitted for Approval in Japan
- Details
- Category: Bayer
Bayer's rivaroxaban (Xarelto®) has been submitted for marketing approval in the prevention of stroke in patients with atrial fibrillation to the Japanese Ministry of Health, Labor and Welfare (MHLW).
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
- Details
- Category: Genzyme
Genzyme Corp., a subsidiary of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease
Forest Laboratories Completes Acquisition of Clinical Data, Inc.
- Details
- Category: Business
Forest Laboratories, Inc. (NYSE: FRX) ("Forest") has successfully completed its acquisition of Clinical Data, Inc. (NASDAQ: CLDA) ("Clinical Data") by means of what is known as a short-form merger under Delaware law.
Nycomed acquires distribution rights to product portfolio in Turkey
- Details
- Category: Nycomed
Nycomed has entered into several agreements with various pharmaceutical companies, including Almirall S.A., Anika Therapeutics, Inc., Bionorica AG, CSL Behring and Helsinn Healthcare SA.
Novartis discontinues clinical trial of Tasigna®
- Details
- Category: Novartis
Novartis is discontinuing a Phase III trial of Tasigna® (nilotinib) for investigational use in the first-line treatment of gastrointestinal stromal tumors (GIST) based on the recommendation of an independent data monitoring committee.
Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled
- Details
- Category: Boehringer Ingelheim
In the business year 2010, Boehringer Ingelheim almost compensated for the anticipated loss of turnover announced in advance last year, nearly achieving the previous year's level.
Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine*) in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-primary endpoints,
More Pharma News ...
- Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
- Amgen Establishes Commercial Operations in Brazil
- Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis
- FDA approves orphan drug vandetanib
- Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
- Pfizer to Sell Capsugel to KKR
- Boehringer Ingelheim's lead hepatitis C compound moves into phase III